149 related articles for article (PubMed ID: 29170809)
21. Hypomethylating agents are effective in shrinking splenomegaly in patients with chronic myelomonocytic leukemia.
Subari S; Patnaik M; Alfakara D; Zblewski D; Hook C; Hashmi S; Hogan W; Litzow M; Al-Kali A
Leuk Lymphoma; 2016 Jul; 57(7):1714-5. PubMed ID: 26462118
[No Abstract] [Full Text] [Related]
22. Activity of azacitidine in chronic myelomonocytic leukemia.
Costa R; Abdulhaq H; Haq B; Shadduck RK; Latsko J; Zenati M; Atem FD; Rossetti JM; Sahovic EA; Lister J
Cancer; 2011 Jun; 117(12):2690-6. PubMed ID: 21656746
[TBL] [Abstract][Full Text] [Related]
23. Leukemia cutis in a patient with chronic myelomonocytic leukemia.
Claßen A; Kitz J; Perske C; Overbeck T; Bertsch HP; Schön MP; Lippert U
J Dtsch Dermatol Ges; 2018 Jan; 16(1):81-83. PubMed ID: 29288601
[No Abstract] [Full Text] [Related]
24. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
25. Interstitial lung disease associated with azacitidine use: a case report.
Sekhri A; Palaniswamy C; Kurmayagari K; Kalra A; Selvaraj DR
Am J Ther; 2012 Mar; 19(2):e98-e100. PubMed ID: 20634671
[TBL] [Abstract][Full Text] [Related]
26. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes.
Alhan C; Westers TM; van der Helm LH; Eeltink C; Huls G; Witte BI; Buchi F; Santini V; Ossenkoppele GJ; van de Loosdrecht AA
Cytometry B Clin Cytom; 2014 May; 86(3):207-15. PubMed ID: 24474614
[TBL] [Abstract][Full Text] [Related]
27. Hydroxyurea-induced Pneumonitis in a Patient with Chronic Myelomonocytic Leukemia: An Autopsy Case.
Imai H; Matsumura N; Yamazaki Y; Kanayama Y; Masuda T; Kuwako T; Kamide Y; Tomizawa T; Matsumoto S; Mitsui T; Kaira K; Ono A; Koga Y; Shibusawa N; Sunaga N; Hisada T; Yokoo H; Yamada M
Intern Med; 2015; 54(24):3171-6. PubMed ID: 26666606
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
[TBL] [Abstract][Full Text] [Related]
29. Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia.
Reiser J; Geissler K
Wien Med Wochenschr; 2023 Feb; 173(1-2):34-40. PubMed ID: 36282401
[TBL] [Abstract][Full Text] [Related]
30. [Acquired hemophilia A associated with chronic myelomonocytic leukemia successfully treated by rituximab and azacitidine].
Dartevel A; Aubanel S; Pica GM; Faurie P; Fauché C; Boué Y; Peigne V
Rev Med Interne; 2018 Aug; 39(8):654-657. PubMed ID: 29653879
[TBL] [Abstract][Full Text] [Related]
31. Rapidly growing ulcer in a patient with neurofibromatosis type I.
Toledo-Alberola F; Guijarro-Llorca J
Actas Dermosifiliogr; 2012 Jan; 103(1):63-4. PubMed ID: 22444509
[No Abstract] [Full Text] [Related]
32. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
33. Leukemia cutis in myelodysplastic syndrome and chronic myelomonocytic leukemia patients treated with adjusted dose 5-azacitidine.
Infante MS; Muñoz C; Heras C; Foncillas MA; González I; Lucea I; Echavarria E; Aramendi T; Hernández JA
Eur J Dermatol; 2015; 25(6):622-3. PubMed ID: 26552844
[No Abstract] [Full Text] [Related]
34. Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine.
Adès L; Sekeres MA; Wolfromm A; Teichman ML; Tiu RV; Itzykson R; Maciejewski JP; Dreyfus F; List AF; Fenaux P; Komrokji RS
Leuk Res; 2013 Jun; 37(6):609-13. PubMed ID: 23415110
[TBL] [Abstract][Full Text] [Related]
35. Monocytic skin nodules in chronic myelomonocytic leukemia: clinical response to decitabine therapy.
Steensma DP; Friday BB
Leuk Lymphoma; 2007 Aug; 48(8):1628-9. PubMed ID: 17701595
[No Abstract] [Full Text] [Related]
36. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.
Aribi A; Borthakur G; Ravandi F; Shan J; Davisson J; Cortes J; Kantarjian H
Cancer; 2007 Feb; 109(4):713-7. PubMed ID: 17219444
[TBL] [Abstract][Full Text] [Related]
37. Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia.
Ricard L; Abisror N; Droin N; Selimoglu-Buet D; Martin A; Soussan M; Willekens C; Deligny C; Fain O; Solary E; Mekinian A;
Leuk Lymphoma; 2018 Oct; 59(10):2503-2505. PubMed ID: 29368535
[No Abstract] [Full Text] [Related]
38. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
39. Chronic myelomonocytic leukemia (CMML)-0 with pleural effusion as first manifestation: A case report.
Hu L; Zheng B; Fu L; Hu M
Medicine (Baltimore); 2020 Oct; 99(44):e23030. PubMed ID: 33126392
[TBL] [Abstract][Full Text] [Related]
40. Treatment of chronic myelomonocytic leukemia with azacitidine.
Wong E; Seymour JF; Kenealy M; Westerman D; Herbert K; Dickinson M
Leuk Lymphoma; 2013 Apr; 54(4):878-80. PubMed ID: 22988826
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
